Movement Disorder Society (MDS)
27^th International Congress of Parkinson's Disease and Movement Disorders in Copenhagen, Denmark (Aug. 27-31, 2023)

• Jackson GR, Sarwar AI, Mandava P, Jamal F. Age at onset and therapeutic efficacy of primidone in essential tremor. Mov Disord. 2023;38(suppl 1):S431.  [View poster]

Movement Disorder Society (MDS)
26^th International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain (Sept. 15-18, 2022)

• Jamal F, Noorbhai I, Jackson G, Sarwar A. Racial differences in essential tremor. Mov Disord. 2022;37 Suppl 2:S427.  [View poster]

Movement Disorder Society (MDS)
Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 17-22, 2021)

• Noorbhai IZ, Jamal F, Jackson G, Sarwar A. Deep brain stimulation surgery and clinical characteristics of essential tremor in a cohort of veterans. Presented at the Movement Disorder Society (MDS), Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 17-22, 2021).   [View poster]

Movement Disorder Society (MDS)
Virtual International Congress of Parkinson's Disease and Movement Disorders. (Sept. 12-16, 2020)

• Shah C, Jamal F, Sarwar A, Jackson G. Use of botulinum toxin: Experience in a cohort of essential tremor patients. Mov Disord. 2020;35 Suppl 1:S699. 

American Academy of Neurology (AAN)
72^nd Annual Meeting in Toronto, Ontario, Canada (April 25 - May 1, 2020)

• Shah C, Jamal F, Jackson G, Sarwar A. Treatment patterns in patients with essential tremor. Neurology. 2020;94(15 Suppl):1555. 

Movement Disorder Society (MDS)
23^rd International Congress of Parkinson's Disease and Movement Disorders in Nice, France (Sept. 22-26, 2019)

• Jamal F, Jackson GR, Moore S, Sarwar AI. Age of onset and diagnosis of essential tremor. Presented at the Movement Disorder Society (MDS), 23^rd International Congress of Parkinson's Disease and Movement Disorders in Nice, France (Sept. 22-26, 2019).   [View poster]

American Academy of Neurology (AAN)
71^st Annual Meeting in Philadelphia, Penn. (May 4-10, 2019)

• Jamal F, Jackson GR, Moore S, Sarwar A. Vitamin D assessment in veterans with Parkinson's disease. Neurology. 2019;92(15 Suppl):P5.8-046.  [View poster]

Movement Disorder Society (MDS)
21^st International Congress of Parkinson's Disease and Movement Disorders in Vancouver, BC, Canada (June 4-8, 2017)

• Bryant M, Hou J-G, Jamal F, Jackson G, Workman C, Protas E. Predictive ability of clinical timed tests for postural instability and gait difficulty in Parkinson's disease. Mov Disord. 2017;32 Suppl 2:S723-4. 
• Jamal F, Jackson GR, Moore S, Sarwar AI. Vitamin D and clinical phenotypes of Parkinson's disease in veterans. Mov Disord. 2017;32 Suppl 2:S897.  [View poster]

Society for Neuroscience (SFN)
46^th Annual Meeting in San Diego, Calif. (Nov. 12-16, 2016)

• Frautschy SA, Hu S, Jones MR, Yang F, Chen P, Jackson GR, et al. Effects of tau peptide aggregation inhibitor in human tau transgenic models. Program No. 513.22. 2016 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2016. Online. 

American Neurological Association (ANA)
140^th Annual Meeting in Chicago, Ill. (Sept. 27-29, 2015)

• Jackson GR, Bryant M, Zaheer F, Protas E. Safety of treadmill exercise testing in Parkinson disease. Ann Neurol. 2015;78 Suppl 19:S61. 

American Academy of Neurology (AAN)
67^th Annual Meeting in Washington, DC (April 18-25, 2015)

• Yassin A, Shroff S, Patel S, Parker A, Berman M, Jackson G. Hemichorea in a patient with diabetic ketoacidosis. Neurology. 2015;84(Meeting Abstracts 1):P3.033. 

Keystone Symposium
New Frontiers in Neurodegenerative Disease Research Meeting in Santa Fe, N.M. (Feb. 5, 2013)

• Jackson GR, Choksi DK, Roy B, Chatterjee S, Sengupta E, Kayed R. Casein kinase Iε phosphorylation of TDP-43 causes oligomerization and enhances toxicity in vivo. Presented at the Keystone Symposium, New Frontiers in Neurodegenerative Disease Research Meeting in Santa Fe, N.M. (Feb. 5, 2013).  

Biochemical Society
Conference: The biology and pathology of tau and its role in tauopathies II in Cambridge, U.K. (Jan. 8-9, 2012)

• Jackson GR. Dissection of tauopathy mechanisms using unbiased genetic screening in the Drosophila retina. Presented at the Biochemical Society, Conference: The biology and pathology of tau and its role in tauopathies II in Cambridge, U.K. (Jan. 8-9, 2012). [Invited Plenary Speaker] 

Society for Neuroscience (SFN)
41^st Annual Meeting in Washington, DC (Nov. 12-16, 2011)

• Bakhoum MF, Jackson GR. Blue cheese/Alfy affects autophagy activation and tau toxicity in a Drosophila model of tauopathy. Program No. 351.20. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online. 
• Jackson GR, Ambegaokar S. RNA binding protein hnRNP K/bancal and its intronic microRNA miR-7 exert opposite effects on tau toxicity through regulation of Insulin Receptor Substrate/chico and GSK-3beta activity. Program No. 144.01. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online. 

2010 American Society for Cell Biology (ASCB)
Annual Meeting in Philadelphia, Penn. (Dec. 11-15, 2010)

• Jackson GR, Ambegaokar S. An unbiased genetic screen for modifiers of tauopathy using both loss and gain of function approaches. Presented at the 2010 American Society for Cell Biology (ASCB), Annual Meeting in Philadelphia, Penn. (Dec. 11-15, 2010).  

Society for Neuroscience (SFN)
40^th Annual Meeting in San Diego, Calif. (Nov. 13-17, 2010)

• Castillo DL, Lasagna-Reeves C, Guerrero-Munoz MJ, Estes DM, Barrett A, Dineley K, et al. Modulation of tau oligomers by passive vaccination. Program No. 347.11. 2010 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2010. Online. 
• Kayed R, Lasagna-Reeves C, Guerrero-Munoz M, Sengupta U, Troncoso J, Jackson GR. Characterization of tau oligomers in Alzheimer's disease. Program No. 527.6. 2010 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2010. Online. 
• Roy B, Ambegaokar SS, Jackson GR. Synergistic effects of tau and alpha-synuclein in dopaminergic neurons. Program No. 458.3. 2010 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2010. Online. 
• Sengupta U, Lasagna-Reeves C, Guerrero-Munoz M, Castillo-Carranza D, Jackson GR, Troncoso J, et al. Tau oligomers in Parkinson disease and dementia with Lewy bodies and their connection with alpha-synuclein oligomers. Program No. 49.10. 2010 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2010. Online. 

Movement Disorder Society (MDS)
14^th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina (June 13-17, 2010)

• Castillo-Carranza DL, Lasagna-Reeves CA, Guerrero-Munoz MJ, Roy B, Jackson GR, Kayed R. Alpha-synuclein oligomers in Parkinson's disease and Lewy body dementia. Mov Disord. 2010;25 Suppl 2:S207. 
• Lasagna-Reeves CA, Jackson GR, Troncoso J, Kayed R. The formation of pore-like amyloid aggregates in movement disorders. Mov Disord. 2010;25 Suppl 2:S208. 
• Lasagna-Reeves CA, Roy B, Bakhoum M, Guerrero-Munoz MJ, Castillo-Carranza DL, Troncoso J, et al. Role of tau oligomers in Parkinson's disease and dementia with Lewy bodies. Mov Disord. 2010;25 Suppl 2:S207. 

NINDS and ALS Association
Workshop: Advances in Disease Modeling for ALS and FTD in San Diego, Calif. (2010)

• Ambegaokar SS, Yusuff T, Choksi DK, Kayed R, Jackson GR. Wing phenotypes produced by misexpression of an ALS-associated TDP-43 mutation include supernumerary veins: A possible clue to signaling pathways. Presented at the NINDS and ALS Association, Workshop: Advances in Disease Modeling for ALS and FTD in San Diego, Calif. (2010).